The Company is targeting the fourth quarter of 2010 for Mammostrat commercialization. ClarientClarientClarient innovative diagnostic technologies with world class pathology expertise to assess and links to characterize cancer Clarient ‘s mission is to be the leader. Cancer Diagnosis cooperative relationships cooperative relations with dedicated healthcare to convict cancer discovery and research into better patient care esomeprazole online without prescription . Clarient main customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine as the new direction set in oncology has. The need for a centralized resource, leading diagnostic technologies, such as flow cytometry and molecular tests Clarient is that resource, having created a state-of – the-art commercial cancer laboratory providing the most advanced oncology testing and diagnostic services. Clarient customers are based in connection with its Internet – based portal, PATHSIT, the high resolution images and critical interpretive reports on our diagnostic testing supplies. Clarient also develops and markets new, Forward-Looking Statementsanion diagnostic markers for therapeutics in breast, prostate, lung, ovarian and colorectal cancers and leukemia / lymphoma.
Forward-Looking Statements – Certain statements in terms of Clarient, Inc. Contain forward-looking statements that involve risks and uncertainties that future events and Clarient ‘s actual results to be materially different from those reflected. Forward-looking statements include but are cause such differences include, but are not limited to: Clarient ‘s ability and expand and expand diagnostic services business, uncertainties inherent in Clarient product development programs, Clarient capability to attract and retain highly skilled managerial, technical and sales and marketing personnel, Clarient ability, compliance with financial and other covenants under its credit line to keep Clarient ‘s ability to successfully manage their payor in-house billing and collections processes, the continuation of favorable third party reimbursement for laboratory tests, changes in the Federal payor regulations or policies, adverse events, adjustments to Medicare reimbursement rates, coverage and reimbursement for Clarient Diagnostics Laboratory may affect services to get Clarient ‘s ability, additional financing on acceptable terms or at all, affect unforeseen expenses or liabilities or other adverse events, cash flow, the uncertainty of success finance in the identification, development and commercialization of new diagnostic tests or novel markers including the Mammostra test, Clarient ‘s ability to develop new diagnostic tests and novel markers and adequate patent protection covering Clarient to the use of these tests and markers also obtained for the Mammostra test, and the amount of resources Clarient determines to novel marker development and commercialization, the risk to Clarient injury claims and the possibility of avoiding the need intellectual property intellectual property from third parties, or settle such claims, failure the applicable regulatory approvals and approvals required to conduct clinical trials, if / when required and / or Clarient to market the services and underlying diagnostic applications received Clarient ability with other technologies and with new competitors in novel cancer diagnostics and dependence on third parties for collaboration in the competition developing new tests, and risks from time to time in Clarient ‘s SEC reports, including quarterly reports on Form 10-Q, current reports on Form 8-K and annual reports on Form 10-K. Recent experience with respect to laboratory services, revenues and results of operations are not necessarily indicative of future results for the reasons set forth above. Read more